Madrigal reports 36-week Phase II data for MGL-3196 in NASH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said MGL-3196 led to significant improvements vs. placebo in disease activity and disease resolution at week 36 in a double-blind, U.S. Phase II trial to treat liver biopsy-confirmed non-alcoholic steatohepatitis (NASH). The company said it

Read the full 394 word article

User Sign In